ZVSA

ZyVersa Therapeutics, Inc. (ZVSA) SWOT Analysis Analysis (2026)

Invetso Score: 1.7/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Strengths

Score: 2.1 (Weak)

ROIC remains deeply negative, indicating ZVSA destroys capital more than peers that at least approach breakeven returns, which weakens long-term positioning.

The reported cash conversion cycle is flat at zero, but unlike stronger peers this does not offset the absence of positive profitability or operating leverage.

No gross or operating margin data are reported, leaving ZVSA without evidence of peer-level margin durability that would support structural strength.

Weaknesses

Score:

Current and quick ratios of 0.05 signal extreme liquidity stress, leaving ZVSA far below peers with workable near-term funding flexibility.

Negative net debt to EBITDA and debt to equity ratios reflect a balance-sheet structure that is not meaningfully supported by earnings, unlike healthier peers.

Deeply negative ROIC shows capital is being deployed without adequate returns, which compounds dilution and financing risk versus better-capitalized competitors.

Missing margin disclosure suggests the business lacks demonstrated operating efficiency, making it structurally weaker than peers with visible cost discipline.

Opportunities

Score:

Any improvement in liquidity would have outsized impact because ZVSA starts from an extremely low current ratio, whereas peers often have more room to absorb shocks.

If capital deployment becomes more disciplined, negative ROIC could narrow toward peer norms, improving credibility with suppliers and investors over time.

The absence of segment concentration data leaves room for future portfolio focus, but peers with clearer segment economics currently appear better positioned.

Threats

Score:

Persistent sub-0.1 liquidity ratios raise going-concern pressure, while peers with stronger working capital can fund operations without immediate balance-sheet strain.

Negative returns on invested capital increase the risk that additional funding simply destroys more value, unlike peers that can reinvest at positive spreads.

Without margin visibility, ZVSA faces a competitive disadvantage in pricing and cost control versus peers that can defend profitability through scale or efficiency.

Overall Score

Score:

ZVSA is structurally weak versus peers because severe liquidity stress and negative capital returns outweigh any limited balance-sheet or operating flexibility.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on ZyVersa Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →